---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-044001"
form_type: "8-K"
ticker: "CODX"
cik: "0001692415"
company_name: "Co-Diagnostics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:38:50.867277+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Co-Diagnostics Q3 revenue $0.6M down from $2.5M; net loss $9.7M ($0.32/share)

## Summary
- Q3 2024 revenue $0.6M ($0.4M grant + $0.2M product) vs $2.5M prior year, down 76%.
- Net loss $9.7M ($0.32 per diluted share) vs $6.0M ($0.20) prior year; operating loss $10.2M.
- Adjusted EBITDA loss $8.8M; cash and securities $37.7M as of Sept 30, 2024.
- FDA 510(k) review ongoing for Co-Dx PCR platform; TB, respiratory, HPV multiplex tests in pipeline.
- India oligonucleotide (Co-Primers) mfg facility inauguration expected early Dec 2024.

## SEC filing metadata
- accession: 0001493152-24-044001
- form_type: 8-K
- ticker: CODX
- cik: 0001692415
- company_name: Co-Diagnostics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1692415/000149315224044001/0001493152-24-044001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1692415/000149315224044001/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-044001
- JSON: https://secwatch.observer/filing/0001493152-24-044001.json
- Plain text: https://secwatch.observer/filing/0001493152-24-044001.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.